Latest Licensing Deals News

Page 7 of 16
Weebit Nano has landed its largest customer yet with Texas Instruments licensing its ReRAM technology, while achieving key technical milestones and doubling its revenue guidance for FY26.
Sophie Babbage
Sophie Babbage
30 Jan 2026
Starpharma reports strong progress in strategic collaborations and internal drug development, alongside a 70% surge in Viraleze™ online sales and a solid $18.2 million cash position.
Ada Torres
Ada Torres
29 Jan 2026
Atomo Diagnostics reported a robust 121% quarter-on-quarter revenue increase to $1.5 million, driven by new orders for its FebriDx Pascal and HIV Self-Test products. The company also secured a global licensing deal for a novel liver function test and expanded manufacturing capacity to support growing demand.
Ada Torres
Ada Torres
28 Jan 2026
Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.
Ada Torres
Ada Torres
23 Jan 2026
Arovella Therapeutics has filed an IND application for its lead CAR-iNKT therapy ALA-101, selected a CRO for its upcoming phase 1 trial, and secured $19.4 million in cash to fund clinical progress and pipeline expansion.
Ada Torres
Ada Torres
23 Jan 2026
Audeara Ltd reported a strong Q2 FY26 with revenues up 274% year-on-year, securing key regulatory approval in China and expanding its global licensing footprint.
Ada Torres
Ada Torres
21 Jan 2026
Atomo Diagnostics has locked in exclusive global rights to a novel liver function test that rapidly detects liver injury, expanding its footprint in point-of-care diagnostics. The test, delivered on Atomo’s Pascal platform, targets drug-induced liver injury and chronic liver conditions with significant commercial potential.
Ada Torres
Ada Torres
20 Jan 2026
AdAlta Limited has raised A$1.2 million through a strategic placement to advance its innovative PD1 armored MSLN CAR-T therapy for solid cancers, reinforcing its unique 'East to West' cellular immunotherapy approach.
Ada Torres
Ada Torres
13 Jan 2026
Origin Energy backs a landmark US$1 billion equity raise for Kraken Technologies, valuing the company at US$8.65 billion and maintaining a significant stake as Kraken prepares to separate from Octopus Energy.
Maxwell Dee
Maxwell Dee
30 Dec 2025
Weebit Nano has raised its FY26 revenue guidance to a minimum of $10 million following the signing of multiple IP licensing agreements with semiconductor fabs and product companies.
Sophie Babbage
Sophie Babbage
29 Dec 2025
Weebit Nano has inked a long-term licensing deal with semiconductor giant Texas Instruments to integrate its advanced ReRAM technology into TI’s embedded processing chips, marking a significant step for next-generation memory solutions.
Sophie Babbage
Sophie Babbage
29 Dec 2025
Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.
Ada Torres
Ada Torres
23 Dec 2025

Browse the archive

Full archive